{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:49:52Z","timestamp":1784616592994,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP22\/00141"],"award-info":[{"award-number":["CP22\/00141"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002943","name":"Departament d'Innovaci\u00f3, Universitats i Empresa, Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2024 FI-1 00075"],"award-info":[{"award-number":["2024 FI-1 00075"]}],"id":[{"id":"10.13039\/501100002943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00415-025-13042-y","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T22:49:48Z","timestamp":1744238988000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Upper limb motor function in individuals with SMA type 2: natural history and impact of therapies"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4762-7591","authenticated-orcid":false,"given":"Laura","family":"Carrera-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Exp\u00f3sito-Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Carolina","family":"\u00d1ungo Garz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pareja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Ortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julita","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Mart\u00ednez-Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Urbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonia","family":"Grimalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francina","family":"Munell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3scar","family":"Garc\u00eda-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obdulia","family":"Moya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Est\u00e9vez-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol","family":"Balsells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Lia","family":"Frongia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Borr\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Puig-Ram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Garc\u00eda Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"L\u00f3pez-Lobato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Pitarch-Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Natera-de Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"13042_CR1","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","volume":"16","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Pera MC, Scoto M et al (2020) Spinal muscular atrophy\u2014insights and challenges in the treatment era. Nat Rev Neurol 16:706\u2013715. https:\/\/doi.org\/10.1038\/s41582-020-00413-4","journal-title":"Nat Rev Neurol"},{"key":"13042_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0960-8966(91)90051-S","volume":"1","author":"V Dubowitz","year":"1991","unstructured":"Dubowitz V (1991) Chaos in classification of the spinal muscular atrophies of childhood. Neuromuscul Disord 1:77\u201380. https:\/\/doi.org\/10.1016\/0960-8966(91)90051-S","journal-title":"Neuromuscul Disord"},{"key":"13042_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0960-8966(94)00075-K","volume":"5","author":"V Dubowitz","year":"1995","unstructured":"Dubowitz V (1995) Chaos in the classification of SMA: a possible resolution. Neuromuscul Disord 5:3\u20135. https:\/\/doi.org\/10.1016\/0960-8966(94)00075-K","journal-title":"Neuromuscul Disord"},{"key":"13042_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","volume":"11","author":"E Mercuri","year":"2012","unstructured":"Mercuri E, Bertini E, Iannaccone ST (2012) Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol 11:443\u2013452. https:\/\/doi.org\/10.1016\/S1474-4422(12)70061-3","journal-title":"Lancet Neurol"},{"key":"13042_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/acn3.51281","volume":"8","author":"M Annoussamy","year":"2021","unstructured":"Annoussamy M, Seferian AM, Daron A et al (2021) Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann Clin Transl Neurol 8:359\u2013373. https:\/\/doi.org\/10.1002\/acn3.51281","journal-title":"Ann Clin Transl Neurol"},{"key":"13042_CR6","doi-asserted-by":"publisher","unstructured":"Coratti G, Cutrona C, Pera MC et al (2021) Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis. Orphanet J Rare Dis 16:430. https:\/\/doi.org\/10.1186\/s13023-021-02065-z","DOI":"10.1186\/s13023-021-02065-z"},{"key":"13042_CR7","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/14737175.2017.1364159","volume":"17","author":"CA Chiriboga","year":"2017","unstructured":"Chiriboga CA (2017) Nusinersen for the treatment of spinal muscular atrophy. Expert Rev Neurother 17:955\u2013962. https:\/\/doi.org\/10.1080\/14737175.2017.1364159","journal-title":"Expert Rev Neurother"},{"key":"13042_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/nejmoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA et al (2018) Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med 378:625\u2013635. https:\/\/doi.org\/10.1056\/nejmoa1710504","journal-title":"N Engl J Med"},{"key":"13042_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","volume":"21","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Deconinck N, Mazzone ES et al (2022) Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 21:42\u201352. https:\/\/doi.org\/10.1016\/S1474-4422(21)00367-7","journal-title":"Lancet Neurol"},{"key":"13042_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M et al (2021) Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med 385:427\u2013435. https:\/\/doi.org\/10.1056\/NEJMoa2102047","journal-title":"N Engl J Med"},{"key":"13042_CR11","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","volume":"91","author":"L Maggi","year":"2020","unstructured":"Maggi L, Bello L, Bonanno S et al (2020) Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry 91:1166\u20131174. https:\/\/doi.org\/10.1136\/jnnp-2020-323822","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13042_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, Wurster CD, G\u00fcnther R et al (2020) Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol 19:317\u2013325. https:\/\/doi.org\/10.1016\/S1474-4422(20)30037-5","journal-title":"Lancet Neurol"},{"key":"13042_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2247","author":"G Baranello","year":"2021","unstructured":"Baranello G, Gorni K, Daigl M et al (2021) Prognostic factors and treatment-effect modifiers in spinal muscular atrophy. Clin Pharmacol Ther. https:\/\/doi.org\/10.1002\/cpt.2247","journal-title":"Clin Pharmacol Ther"},{"key":"13042_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","volume":"39","author":"J Erdos","year":"2022","unstructured":"Erdos J, Wild C (2022) Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data. Eur J Paediatr Neurol 39:1\u201310","journal-title":"Eur J Paediatr Neurol"},{"key":"13042_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02547-8","author":"A Pechmann","year":"2022","unstructured":"Pechmann A, Behrens M, D\u00f6rnbrack K et al (2022) Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-year SMArtCARE registry study. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/s13023-022-02547-8","journal-title":"Orphanet J Rare Dis"},{"key":"13042_CR16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.nmd.2020.07.004","volume":"30","author":"G Coratti","year":"2020","unstructured":"Coratti G, Lucibello S, Pera MC et al (2020) Gain and loss of abilities in type II SMA: a 12-month natural history study. Neuromuscul Disord 30:765\u2013771. https:\/\/doi.org\/10.1016\/j.nmd.2020.07.004","journal-title":"Neuromuscul Disord"},{"key":"13042_CR17","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1212\/WNL.0b013e318271f7e4","volume":"79","author":"P Kaufmann","year":"2012","unstructured":"Kaufmann P, McDermott MP, Darras BT et al (2012) Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology 79:1889\u20131897. https:\/\/doi.org\/10.1212\/WNL.0b013e318271f7e4","journal-title":"Neurology"},{"key":"13042_CR18","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/mus.27384","volume":"64","author":"G Coratti","year":"2021","unstructured":"Coratti G, Pera MC, Montes J et al (2021) Different trajectories in upper limb and gross motor function in spinal muscular atrophy. Muscle Nerve 64:552\u2013559. https:\/\/doi.org\/10.1002\/mus.27384","journal-title":"Muscle Nerve"},{"key":"13042_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28041","author":"E Milev","year":"2024","unstructured":"Milev E, Selby V, Wolfe A et al (2024) Assessment of the upper limb function, strength, and mobility in treatment-naive children with spinal muscular atrophy types 2 and 3. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.28041","journal-title":"Muscle Nerve"},{"key":"13042_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3233\/JND-230211","volume":"11","author":"A Wolfe","year":"2024","unstructured":"Wolfe A, Stimpson G, Ramsey D et al (2024) Disease trajectories in the revised hammersmith scale in a cohort of untreated patients with spinal muscular atrophy types 2 and 3. J Neuromuscul Dis 11:665\u2013677. https:\/\/doi.org\/10.3233\/JND-230211","journal-title":"J Neuromuscul Dis"},{"key":"13042_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2024.08.006","volume":"44","author":"G Coratti","year":"2024","unstructured":"Coratti G, Civitello M, Rohwer A et al (2024) Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the revised upper limb module. Neuromuscul Disord 44:104449. https:\/\/doi.org\/10.1016\/j.nmd.2024.08.006","journal-title":"Neuromuscul Disord"},{"key":"13042_CR22","doi-asserted-by":"publisher","first-page":"e1241","DOI":"10.1212\/WNL.0000000000008166","volume":"93","author":"E Mercuri","year":"2019","unstructured":"Mercuri E, Lucibello S, Pera MC et al (2019) Long-term progression in type II spinal muscular atrophy: a retrospective observational study. Neurology 93:e1241\u2013e1247. https:\/\/doi.org\/10.1212\/WNL.0000000000008166","journal-title":"Neurology"},{"key":"13042_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2021.03.012","author":"G Coratti","year":"2021","unstructured":"Coratti G, Pane M, Lucibello S et al (2021) Age related treatment effect in type II spinal muscular atrophy pediatric patients treated with nusinersen. Neuromuscul Disord. https:\/\/doi.org\/10.1016\/j.nmd.2021.03.012","journal-title":"Neuromuscul Disord"},{"key":"13042_CR24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J et al (2017) Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve 55:869\u2013874. https:\/\/doi.org\/10.1002\/mus.25430","journal-title":"Muscle Nerve"},{"key":"13042_CR25","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.nmd.2011.02.014","volume":"21","author":"E Mazzone","year":"2011","unstructured":"Mazzone E, Bianco F, Martinelli D et al (2011) Assessing upper limb function in nonambulant SMA patients: development of a new module. Neuromuscul Disord 21:406\u2013412. https:\/\/doi.org\/10.1016\/j.nmd.2011.02.014","journal-title":"Neuromuscul Disord"},{"key":"13042_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.nmd.2021.10.009","volume":"32","author":"G Coratti","year":"2022","unstructured":"Coratti G, Carmela Pera M, Montes J et al (2022) Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes. Neuromuscul Disord 32:36\u201342. https:\/\/doi.org\/10.1016\/j.nmd.2021.10.009","journal-title":"Neuromuscul Disord"},{"key":"13042_CR27","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.nmd.2020.07.005","volume":"30","author":"G Coratti","year":"2020","unstructured":"Coratti G, Pera MC, Lucibello S et al (2020) Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. Neuromuscul Disord 30:756\u2013764. https:\/\/doi.org\/10.1016\/j.nmd.2020.07.005","journal-title":"Neuromuscul Disord"},{"key":"13042_CR28","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mus.26419","volume":"59","author":"MC Pera","year":"2019","unstructured":"Pera MC, Coratti G, Mazzone ES et al (2019) Revised upper limb module for spinal muscular atrophy: 12 month changes. Muscle Nerve 59:426\u2013430. https:\/\/doi.org\/10.1002\/mus.26419","journal-title":"Muscle Nerve"},{"key":"13042_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121799","volume":"10","author":"AM Seferian","year":"2015","unstructured":"Seferian AM, Moraux A, Canal A et al (2015) Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial. PLoS ONE 10:e0121799. https:\/\/doi.org\/10.1371\/journal.pone.0121799","journal-title":"PLoS ONE"},{"key":"13042_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.nmd.2014.11.008","volume":"25","author":"S Sivo","year":"2015","unstructured":"Sivo S, Mazzone E, Antonaci L et al (2015) Upper limb module in non-ambulant patients with spinal muscular atrophy: 12 month changes. Neuromuscul Disord 25:212\u2013215. https:\/\/doi.org\/10.1016\/j.nmd.2014.11.008","journal-title":"Neuromuscul Disord"},{"key":"13042_CR31","doi-asserted-by":"publisher","unstructured":"Segovia-Simon S, Nungo C, Costa JV et al (2022) P.42 CuidAME: registry for longitudinal data collection of Spanish SMA patients. Neuromuscul Disord 32:S60. https:\/\/doi.org\/10.1016\/j.nmd.2022.07.078","DOI":"10.1016\/j.nmd.2022.07.078"},{"key":"13042_CR32","doi-asserted-by":"publisher","first-page":"7S18","DOI":"10.1016\/S0929-693X(20)30272-4","volume":"27","author":"C Canc\u00e8s","year":"2020","unstructured":"Canc\u00e8s C, Richelme C, Barnerias C, Espil C (2020) Clinical features of spinal muscular atrophy (SMA) type 2. Arch P\u00e9diatr 27:7S18-7S22. https:\/\/doi.org\/10.1016\/S0929-693X(20)30272-4","journal-title":"Arch P\u00e9diatr"},{"key":"13042_CR33","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/jnnp-2016-314292","volume":"88","author":"RI Wadman","year":"2017","unstructured":"Wadman RI, Stam M, Gijzen M et al (2017) Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0\u20134. J Neurol Neurosurg Psychiatry 88:365\u2013367. https:\/\/doi.org\/10.1136\/jnnp-2016-314292","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13042_CR34","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1177\/0883073811420294","volume":"26","author":"AM Glanzman","year":"2011","unstructured":"Glanzman AM, O\u2019Hagen JM, McDermott MP et al (2011) Validation of the expanded hammersmith functional motor scale in spinal muscular atrophy type II and III. J Child Neurol 26:1499\u20131507. https:\/\/doi.org\/10.1177\/0883073811420294","journal-title":"J Child Neurol"},{"key":"13042_CR35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3233\/JND-190462","volume":"7","author":"S Dunaway Young","year":"2020","unstructured":"Dunaway Young S, Montes J, Salazar R et al (2020) Scoliosis surgery significantly impacts motor abilities in higher-functioning individuals with spinal muscular atrophy. J Neuromuscul Dis 7:183\u2013192. https:\/\/doi.org\/10.3233\/JND-190462","journal-title":"J Neuromuscul Dis"},{"key":"13042_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2022.09.008","author":"Y Kobayashi","year":"2022","unstructured":"Kobayashi Y, Ishikawa N, Tateishi Y et al (2022) Evaluation of cerebrospinal fluid biomarkers in pediatric patients with spinal muscular atrophy. Brain Dev. https:\/\/doi.org\/10.1016\/j.braindev.2022.09.008","journal-title":"Brain Dev"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13042-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13042-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13042-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:42:20Z","timestamp":1747658540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13042-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["13042"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13042-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Laura Carrera-Garc\u00eda is involved as a subinvestigator in clinical trials from Biogen, and Roche. She has received honoraria for speaking engagements, and compensation for attending conferences from Biogen, and Roche. Jessica Exp\u00f3sito-Escudero is involved as a subinvestigator in clinical trials from Biogen, and Roche. She has received honoraria for speaking engagements, and compensation for attending conferences from Novartis and Roche. Nancy Carolina \u00d1ungo Garz\u00f3n is involved as a subinvestigator in clinical trials from different promotors. She has received honoraria for speaking engagements, and compensation for attending conferences from Roche. Miguel A. Fern\u00e1ndez-Garc\u00eda is involved as a subinvestigator in clinical trials and received honoraria for speaking engagements, and advisory boards from Biogen, Roche and Novartis. Carlos Ortez is involved as a subinvestigator in clinical trials and received honoraria for speaking engagements, and advisory boards from Biogen, Roche and Novartis. Julita Medina is involved as a clinical evaluator in clinical trials from Biogen, and Roche. She has received honoraria for speaking engagements, and participation in advisory boards from Biogen, and Roche Obdulia Moya is involved as a clinical evaluator in clinical trials from Biogen, and Roche. She has received honoraria for speaking engagements, and participation in advisory boards from Roche Sandra Roca is involved as a clinical evaluator in clinical trials from Biogen, and Roche. She has received honoraria for speaking engagements, and participation in advisory boards from Biogen, and Roche. Mar Garc\u00eda Romero is involved as principal investigator in clinical trials and received honoraria for speaking engagements, and advisory boards from Biogen, Roche, and Novartis. Inmaculada Pitarch-Castellano\u00a0is involved as principal investigator in clinical trials and received honoraria for speaking engagements, and advisory boards from Biogen, Roche and Novartis. Daniel Natera-de Benito is supported by the Miguel Servet program from Instituto de Salud Carlos III, Spain (CP22\/00141) and, additionally, has received honoraria for speaking engagements, participation in advisory boards, and compensation for attending conferences from Biogen, Novartis, and Roche. Andr\u00e9s Nascimento is involved as principal investigator in clinical trials and received honoraria for speaking engagements, and advisory boards from Biogen, Roche, Scholar Rock and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All participants gave written informed consent, obtained according to the Declaration of Helsinki and approved by the medical ethical committee of the Fundaci\u00f3 Sant Joan de d\u00e9u (PIC-137-15 and PIC-188-18).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}],"article-number":"331"}}